| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 1. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | sodium valproate (Episenta®) |
| Formulation | 150 mg, 300 mg, 500 mg and 1000 mg prolonged-release granules |
| Reference number | 2012 |
| Indication | Treatment of all forms of epilepsy. Treatment of manic episode in bipolar disorder when lithium is contraindicated or not tolerated. The continuation of treatment after manic episode could be considered in patients who have responded to sodium valproate for acute mania |
| Company | Desitin Pharma Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 24/05/2013 |